期刊文献+

6种止吐用药方案预防高致吐风险化疗引起恶心呕吐临床效果的网状meta分析 被引量:9

Network Meta-analysis of the Clinical Efficacy of Six Kinds of Antiemetic Regimens in the Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy
原文传递
导出
摘要 目的采用网状meta分析评价6种止吐用药方案预防高致吐风险化疗(highly emetogenic chemotherapy,HEC)引起的恶心呕吐的疗效。方法计算机检索中国知网、万方数据、维普医药、Pub Med、Embase和Cochrane Library(2019年第8期),检索时限至2019年9月1日,收集5-羟色胺3受体抑制剂[包括第1代5-HT3和第2代5-HT3帕洛诺司琼(palonosetron,PAL)]+地塞米松(dexamethasone,DEX)、神经激肽1受体抑制剂(NK-1 receptor antagonist,NK-1RA)+5-HT3+DEX、奥氮平(olanzapine,OLZ)+5-HT3+DEX、NEPA(奈妥吡坦300mg+PAL0.50mg)+DEX预防化疗所致恶心呕吐(chemotherapy-inducednauseaand vomiting,CINV)的随机对照试验(randomized controlled trials,RCTs),由2名评价员独立筛选文献、提取数据,并按照Cochrane偏倚风险评估工具评价文献质量,采用Stata 15.0统计软件进行网状meta分析。结果共纳入18项RCTs,合计8076例患者。网状meta分析结果显示:与5-HT3+DEX比较,NEPA+DEX、NK-1RA+5-HT3+DEX、NK-1RA+PAL+DEX和OLZ+PAL+DEX预防CINV急性完全缓解率高于5-HT3+DEX组,差异有统计学意义(P<0.05),概率排序为OLZ+PAL+DEX>NK-1RA+PAL+DEX>NK-1RA+5-HT3+DEX>NEPA+DEX>PAL+DEX=5-HT3+DEX。与5-HT3+DEX比较,NEPA+DEX、NK-1RA+5-HT3+DEX、NK-1RA+PAL+DEX、OLZ+PAL+DEX和PAL+DEX预防CINV延迟期完全缓解率高于5-HT3+DEX组,差异有统计学意义(P<0.05),概率排序为NK-1RA+PAL+DEX>OLZ+PAL+DEX>NEPA+DEX>NK-1RA+5-HT3+DEX=PAL+DEX=5-HT3+DEX。与5-HT3+DEX比较,NEPA+DEX、NK-1RA+5-HT3+DEX和NK-1RA+PAL+DEX预防CINV持续期完全缓解率高于5-HT3+DEX组,差异有统计学意义(P<0.05),概率排序为NK-1RA+PAL+DEX>OLZ+PAL+DEX>NEPA+DEX>NK-1RA+5-HT3+DEX>PAL+DEX>5-HT3+DEX。结论通过网状meta分析发现,OLZ+PAL+DEX是预防HEC致急性CINV最有效方案,而NK-1RA+PAL+DEX是预防迟发性和持续期CINV最有效方案。 OBJECTIVE To evaluate the efficacy of six antiemetic regimens in the prevention of nausea and vomiting caused by highly emetogenic chemotherapy(HEC)by network meta analysis.METHODS Retrieved from CNKI,Wanfang database,VIP,PubMed,EMbase and Cochrane Library(Issue 8,2019),retrieval time was limited to 1 September 2019.Randomized controlled trials(RCTs)about serotonin-3 receptor antagonist[include first-generation 5-HT3 and second-generation 5-HT3 palonosetron(PAL)]+dexamethasone(DEX),NK-1 receptor antagonist(NK-1 RA)+5-HT3+DEX,olanzapine(OLZ)+5-HT3+DEX and NEPA(netupitant 300 mg+PAL 0.50 mg)+DEX in the prevention of chemotherapy-induced nausea and vomiting(CINV)were collected.The data were extracted by 2 evaluators and the quality of the literature was evaluated according to the cochrane bias risk assessment tool.The network meta-analysis was carried out by using Stata 15.0 statistical software.RESULTS A total of 18 RCTs were included,involving 8076 patients.Results of network meta-analysis showed that:compared with 5-HT3+DEX,NEPA+DEX,NK-1 RA+5-HT3+DEX,NK-1 RA+PAL+DEX and OLZ+PAL+DEX could significantly improve CINV acute complete response,with statistical significance(P<0.05).The probability ranking was OLZ+PAL+DEX>NK-1 RA+PAL+DEX>NK-1 RA+5-HT3+DEX>NEPA+DEX>PAL+DEX=5-HT3+DEX.Compared with 5-HT3+DEX,NEPA+DEX,NK-1 RA+5-HT3+DEX,NK-1 RA+PAL+DEX,OLZ+PAL+DEX and PAL+DEX could significantly improve CINV delayed complete response,with statistical significance(P<0.05).The probability ranking was NK-1 RA+PAL+DEX>OLZ+PAL+DEX>NEPA+DEX>NK-1 RA+5-HT3+DEX=PAL+DEX=5-HT3+DEX.Compared with 5-HT3+DEX,NEPA+DEX,NK-1 RA+5-HT3+DEX and NK-1 RA+PAL+DEX could significantly improve CINV overall complete response,with statistical significance(P<0.05).The probability ranking was NK-1 RA+PAL+DEX>OLZ+PAL+DEX>NEPA+DEX>NK-1 RA+5-HT3+DEX>PAL+DEX>5-HT3+DEX.CONCLUSION By network meta-Analysis,OLZ+PAL+DEX is most likely to be the most effective intervention to prevent CINV caused by HEC,while NK-1 RA+PAL+DEX is most likely to be the most effective intervention to prevent delayed and persistent CINV.
作者 林琴 林王椿 李成贻 蔡忠捷 LIN Qin;LIN Wangchun;LI Chengyi;CAI Zhongjie(Mindong Hospital Affiliated to Fujian Medical University,Fu’an 355000,China)
出处 《中国现代应用药学》 CAS CSCD 北大核心 2020年第20期2526-2534,共9页 Chinese Journal of Modern Applied Pharmacy
关键词 化疗所致恶心呕吐 高致吐风险化疗 疗效 网状meta分析 chemotherapy-induced nausea and vomiting highly emetogenic chemotherapy therapeutic efficacy network meta-analysis
  • 相关文献

参考文献12

二级参考文献84

  • 1Anna Chmielewska,Hania Szajewska.Systematic review of randomised controlled trials:Probiotics for functional constipation[J].World Journal of Gastroenterology,2010,16(1):69-75. 被引量:56
  • 2杨新杰,张树才.雷莫司琼预防肺癌顺铂化疗所致恶心呕吐效果的随机对照临床研究[J].中国肺癌杂志,2005,8(4):322-325. 被引量:13
  • 3陈映霞,秦叔逵,程颖,陈振东,李进,张清媛,潘良熹.盐酸帕洛诺司琼预防化疗性恶心呕吐的多中心双盲随机对照临床研究[J].临床肿瘤学杂志,2007,12(3):161-165. 被引量:48
  • 4NCCN Clinical Practice Guidelines in Oncology: Antiemesis. version 1. 2014[EB/OL] .[2014-02-25]. http://www. nccn. orgl professionalsl physician_glsl pdfl antiemesis. pdf.
  • 5MASCC/ESMO. Antiemetic Guidelines 2013[EB/OL].[2014- 02-25]. http://www. mascc. orgl antiemetic-guidelines; 2013 MASccTM?.
  • 6Gralla RJ, Osoba D, Krismg, et al. Recommendations for the use of anti emetics : evidence-based, clinical practice guidelines[J] .J Clin Oncol, 1999, 17(9): 2971-2994.
  • 7徐建国.手术后恶心呕吐(PONV)防治快捷指南[EB/OL].2012[2014—02-25].http://www.csao].cn/bencandy.php?aid=6246.
  • 8Apfel CC, Heidrich FM,Jukar-Rao S, et al. Evidence-based analysis of risk factors for postoperative nausea and vomiting[J] . BrJ Anaesth, 2012, 109(5): 742-753.
  • 9Warr DG, Grunberg SM, Gralla RJ, et al. The oral NK 1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting- Pooled data from 2 randomised, double-blind, placebo controlled trials[J]. EurJ Cancer, 2005, 41(9): 1278-1285.
  • 10Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron[J]. Ann Oncol, 2003, 14 ( 10) : 1570-1577.

共引文献525

同被引文献132

引证文献9

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部